Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment
Executive Summary
Celgene has been vilified in the political realm for excessive price increases, which hasn’t helped its stock performance over past year and a half.
You may also be interested in...
US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed
Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
Bristol/Celgene A Record-Setting Merger, If It Happens
The $74bn mega-merger would be the third largest in biopharma history, but some analysts wonder if other suitors will try to acquire Bristol before the deal closes.
Arnold Foundation Will Retain Drug Pricing Focus As Health Care Agenda Grows
In an interview with the Pink Sheet, Laura and John Arnold Foundation VP Health Care Mark Miller discusses the foundation’s ongoing drug pricing priorities.